Search Results

SRUK says Energy companies must step up support for people with Raynaud's.

As high bills continue to threaten the health of those living with the debilitating condition; SRUK is appealing to energy companies to provide financial assistance to them.

Sharing Data to Improve Lives: The SRUK Patient Registry Survey

SRUK is developing a Patient Registry, with the aim of improving outcomes for people diagnosed with Scleroderma or Raynaud's. Our Registry will be a secure, anonymous database, containing health information about people living with the conditions. It will be used to improve our understanding of Scleroderma and Raynaud's and how different people are affected over time, to help accelerate research into new and better treatments designed to improve quality of life. Read on to find out what we learned through the SRUK Patient Registry Survey, and how it will help shape our Patient Registry.

STAR turns 1! Here’s what we learned from the Symptom Tracking App for Raynaud’s in 2022

January 2023 marked the 1st Anniversary of the SRUK STAR App. The data contained within the app helps facilitate research into Raynaud’s, allowing us to learn more about the condition and how it affects our community. Read on to find out more about the STAR App and what your data has shown us so far!

Raynaud's Awareness Month 2023

SRUK calls on public to write to their MP to help keep heating affordable for people with Raynaud's

Government Must Act on Cost of Living to Protect Health of Millions With Raynaud's, Says SRUK

SRUK Survey highlights the devastating impact of the cost-of-living crisis and high energy bills for people with Raynaud's.

RAIRDA Report - Resetting the Balance

The Rare Autoimmune Rheumatic Disease Alliance (RAIRDA) which SRUK is a member of, has released a report highlighting ‘alarming disparities in the quality of care and treatment’ received by people living with rare autoimmune rheumatic diseases (RAIRDs).

Winter Vaccinations: Get Your COVID-19 Boosters & Flu Vaccines Now!

To help protect those at risk from COVID-19 & flu, the NHS is currently offering flu vaccines and an autumn COVID booster to those with weakened immune systems, the over 50s, and household members of those who are deemed clinically vulnerable. These vaccines can reduce your chances of catching the viruses and getting seriously ill as a result of them. It's as important as ever to make sure that you, and those in close contact to you, are protected from infection before winter rolls around, so read more about how to get both vaccines here!

Reducing Uncertainty in the Progression of Lung Fibrosis in Scleroderma Patients

Having scleroderma often means living with uncertainty around how the disease will progress over time, and the effect that this could have on future quality of life. New research funded by SRUK aims to help address the impact of this ‘prognostic uncertainty’, by using indicators that will predict disease progression and ultimately improve treatment options.

‘Olive Ayoub Intermediate to Late-Stage Post-Doctoral Research Fellowship’ Opens for Applications on 29th June

On 29th June, Scleroderma & Raynaud’s UK will open applications for the Olive Ayoub Intermediate to Late-Stage Post-doctoral Research Fellowship, which will enable one exceptional, non-tenured post-doctoral researcher to transition from postdoc to research leader in the field of scleroderma.

Identifying Scleroderma Patients at Risk of Pulmonary Hypertension - US Study Provides Potential Biomarker for the Condition

A new US study has found that scleroderma patients who test positive for ‘anti-Th/To antibodies’ are at higher risk of developing pulmonary hypertension (PH) in comparison to other patients, which could enable the earlier detection and more effective management of one of scleroderma’s most serious complications.

Mum Whose Daughters Have Scleroderma Helps SRUK Produce Schools Guide

Both of Alison's daughters have scleroderma, and having experienced the lack of understanding around the condition, she set out to help SRUK create a guide to scleroderma for schools.

Developing the Next Generation of Medicine

SRUK co-funds a MRC Clinical Research Training Fellowship to advance research into treatments for interstitial lung disease.